Par Drugs And Chemicals Limited has informed the Exchange regarding Outcome of Board Meeting held on August 07, 2025.
PAR · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Par Drugs and Chemicals' board, at its meeting on August 7, 2025, approved the unaudited standalone financial results for Q1 FY26 (quarter ended June 30, 2025). Revenue from operations rose to Rs. 2,604.64 lakhs, up about 15% from Rs. 2,260.56 lakhs in the same quarter last year, while total income stood at Rs. 2,788.31 lakhs. Profit after tax jumped to Rs. 332.81 lakhs (vs Rs. 253.31 lakhs in Q1 FY25), with basic and diluted EPS of Rs. 2.70 versus Rs. 2.06 a year ago. The statutory auditor, Sarupria Somani & Associates, issued an unmodified limited review report with no qualifications. The board also noted renewal of an existing Rs. 161 lakh banking facility from Kotak Mahindra Bank with no change in limit, and reviewed investor grievances (none pending) and the corporate governance report. The company operates only in the API manufacturing segment and has no subsidiaries.
Strong year-on-year growth in both revenue and profit, with PAT up roughly 31%, signals healthy operational performance for shareholders. The clean auditor report, zero investor complaints, and unchanged banking facility suggest financial stability without negative triggers.